These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 26232882)
1. Structural and functional insights into sclerostin-glycosaminoglycan interactions in bone. Salbach-Hirsch J; Samsonov SA; Hintze V; Hofbauer C; Picke AK; Rauner M; Gehrcke JP; Moeller S; Schnabelrauch M; Scharnweber D; Pisabarro MT; Hofbauer LC Biomaterials; 2015 Oct; 67():335-45. PubMed ID: 26232882 [TBL] [Abstract][Full Text] [Related]
2. The promotion of osteoclastogenesis by sulfated hyaluronan through interference with osteoprotegerin and receptor activator of NF-κB ligand/osteoprotegerin complex formation. Salbach-Hirsch J; Kraemer J; Rauner M; Samsonov SA; Pisabarro MT; Moeller S; Schnabelrauch M; Scharnweber D; Hofbauer LC; Hintze V Biomaterials; 2013 Oct; 34(31):7653-61. PubMed ID: 23871544 [TBL] [Abstract][Full Text] [Related]
3. Sulfated hyaluronan improves bone regeneration of diabetic rats by binding sclerostin and enhancing osteoblast function. Picke AK; Salbach-Hirsch J; Hintze V; Rother S; Rauner M; Kascholke C; Möller S; Bernhardt R; Rammelt S; Pisabarro MT; Ruiz-Gómez G; Schnabelrauch M; Schulz-Siegmund M; Hacker MC; Scharnweber D; Hofbauer C; Hofbauer LC Biomaterials; 2016 Jul; 96():11-23. PubMed ID: 27131598 [TBL] [Abstract][Full Text] [Related]
4. Structural and functional insights into the interaction of sulfated glycosaminoglycans with tissue inhibitor of metalloproteinase-3 - A possible regulatory role on extracellular matrix homeostasis. Rother S; Samsonov SA; Hofmann T; Blaszkiewicz J; Köhling S; Moeller S; Schnabelrauch M; Rademann J; Kalkhof S; von Bergen M; Pisabarro MT; Scharnweber D; Hintze V Acta Biomater; 2016 Nov; 45():143-154. PubMed ID: 27545813 [TBL] [Abstract][Full Text] [Related]
5. The effect of the degree of sulfation of glycosaminoglycans on osteoclast function and signaling pathways. Salbach J; Kliemt S; Rauner M; Rachner TD; Goettsch C; Kalkhof S; von Bergen M; Möller S; Schnabelrauch M; Hintze V; Scharnweber D; Hofbauer LC Biomaterials; 2012 Nov; 33(33):8418-29. PubMed ID: 22954516 [TBL] [Abstract][Full Text] [Related]
6. Sulfated glycosaminoglycans exploit the conformational plasticity of bone morphogenetic protein-2 (BMP-2) and alter the interaction profile with its receptor. Hintze V; Samsonov SA; Anselmi M; Moeller S; Becher J; Schnabelrauch M; Scharnweber D; Pisabarro MT Biomacromolecules; 2014 Aug; 15(8):3083-92. PubMed ID: 25029480 [TBL] [Abstract][Full Text] [Related]
8. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors. Choi J; Lee K; Kang M; Lim SK; Tai No K Bioorg Med Chem Lett; 2018 Apr; 28(6):1116-1121. PubMed ID: 29486968 [TBL] [Abstract][Full Text] [Related]
9. Collagen/glycosaminoglycan coatings enhance new bone formation in a critical size bone defect - A pilot study in rats. Förster Y; Bernhardt R; Hintze V; Möller S; Schnabelrauch M; Scharnweber D; Rammelt S Mater Sci Eng C Mater Biol Appl; 2017 Feb; 71():84-92. PubMed ID: 27987780 [TBL] [Abstract][Full Text] [Related]
10. NMR structure of the Wnt modulator protein Sclerostin. Weidauer SE; Schmieder P; Beerbaum M; Schmitz W; Oschkinat H; Mueller TD Biochem Biophys Res Commun; 2009 Feb; 380(1):160-5. PubMed ID: 19166819 [TBL] [Abstract][Full Text] [Related]
12. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503 [TBL] [Abstract][Full Text] [Related]
13. Characterization of the interaction of sclerostin with the low density lipoprotein receptor-related protein (LRP) family of Wnt co-receptors. Holdsworth G; Slocombe P; Doyle C; Sweeney B; Veverka V; Le Riche K; Franklin RJ; Compson J; Brookings D; Turner J; Kennedy J; Garlish R; Shi J; Newnham L; McMillan D; Muzylak M; Carr MD; Henry AJ; Ceska T; Robinson MK J Biol Chem; 2012 Aug; 287(32):26464-77. PubMed ID: 22696217 [TBL] [Abstract][Full Text] [Related]
14. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6. Bourhis E; Wang W; Tam C; Hwang J; Zhang Y; Spittler D; Huang OW; Gong Y; Estevez A; Zilberleyb I; Rouge L; Chiu C; Wu Y; Costa M; Hannoush RN; Franke Y; Cochran AG Structure; 2011 Oct; 19(10):1433-42. PubMed ID: 21944579 [TBL] [Abstract][Full Text] [Related]
15. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. Choi HY; Dieckmann M; Herz J; Niemeier A PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252 [TBL] [Abstract][Full Text] [Related]
16. The binding between sclerostin and LRP5 is altered by DKK1 and by high-bone mass LRP5 mutations. Balemans W; Piters E; Cleiren E; Ai M; Van Wesenbeeck L; Warman ML; Van Hul W Calcif Tissue Int; 2008 Jun; 82(6):445-53. PubMed ID: 18521528 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the interaction of interleukin-8 with hyaluronan, chondroitin sulfate, dermatan sulfate and their sulfated derivatives by spectroscopy and molecular modeling. Pichert A; Samsonov SA; Theisgen S; Thomas L; Baumann L; Schiller J; Beck-Sickinger AG; Huster D; Pisabarro MT Glycobiology; 2012 Jan; 22(1):134-45. PubMed ID: 21873605 [TBL] [Abstract][Full Text] [Related]